Comparison of adjuvant chemotherapy use in African American women with breast cancer versus the rest of the adjuvant breast cancer population
| Autor: | W. Bule, J. M. Quigley, J. Runyun, A. Moseley |
|---|---|
| Rok vydání: | 2006 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 24:6069-6069 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2006.24.18_suppl.6069 |
| Popis: | 6069 Background: Demographics, specifically race have been discussed as reasons for disparity of care in the breast cancer setting. Methods: We used a validated database with physician entered, de-identified patient data from a randomized sample of oncologists in the US. Physicians capture de-identified data on up to 20 patients per week using a clinically validated, software driven algorithm. We evaluated all female patient records with breast cancer that were receiving adjuvant chemotherapy for their disease, from January 2005 through November 2005. All data elements are required fields, allowing for a complete patient record with each entry, including race, age, stage, nodal status, hormone status, her 2 status and chemotherapy treatments. Results: During this 11 month period, 4465 adjuvant breast cancer records were received. All were included in this analysis. Of the 4465 patient records, 69%( n=3085) were Caucasian, 18% (n= 830) were African American, 9% (n=408) were Hispanic/Latino and 4% were ‘other, which included, Native American and Asian patients. The average age for Caucasian patients was 56 years; average age for African American patients was 55 years, average age for Hispanic/Latino patients 51 years, average for all other patients 55 years. 63% of the Caucasian patients had node + disease, 59% of African Americans had node + disease, 62% of Hispanic/Latinos had node + disease, and 61% of all others had node + disease. Top treatment regimens for Caucasian patients were AC followed by Taxol (dose dense), AC, AC followed by Taxotere (dose dense), ACT (Taxotere) and CMF. Top treatment regimens for African Americans were AC followed by Taxol (dose dense), AC, AC followed by Taxotere (dose dense), ACT (Taxotere) and FAC. Conclusions: In this clinically similar patient population there was no difference in adjuvant chemotherapy selected based upon race. Further evaluations of treatment selections, including, surgery, radiation and endocrine therapy by race are warranted. No significant financial relationships to disclose. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|